$TGODF Showcases Hamilton, Valleyfield Facilities through Analyst Site Visits

$GGBXF New Report Pegs U.S. CBD Retail Sales at $10 billion by 2024

October 22, 2019

Palm Beach, FL – October 22, 2019 – CBD retail sales just in the U.S. are expected to pass $1 billion – a 133% jump year over year, as noted by the 2019 Hemp & CBD Industry Factbook.  By 2024, sales could balloon to $10 billion.  “The recent surge of consumer demand for CBD, coupled with increasingly easy access to CBD products, is expected to drive retail sales to about $1.1 billion-$1.3 billion in 2019,” said Kristen Nichols, editor of the 2^nd Annual Hemp & CBD Industry Factbook. “We project retail CBD sales will increase to $10.3 billion by 2024, a five-year compound annual growth rate of 54%.”  That’s opening a wide range of opportunity for companies including The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF), Aphria Inc. (NYSE:APHA)(TSX:APHA), Charlotte’s Web Holdings Inc. (CSE:CWEB) (OTCQX:CWBHF), Aurora Cannabis Inc. (NYSE:ACB)(TSX:ACB), and Green Growth Brands Inc.(CSE:GGB) (OTCQB:GGBXF).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced that seasoned marketing professional Karla Cheon has been appointed as Vice President, Marketing of Yield Growth, effective October 21, 2019.  Cheon has a proven track record as a marketer for successful, growing brands. As a testament to her unique combination of marketing insight, brand-building talent and business acumen, she was selected to lead or partner on the marketing aspects of key strategic growth initiatives at Aritzia during her nearly 15-year tenure at the leading fashion retailer: Aritzia’s expansion into the USA (2007) and Quebec (2013), its eCommerce launch (2012), and its Initial Public Offering (2016). Aritzia is a vertically integrated, innovative design house of exclusive fashion brands. It reported net revenue of $874 million in Fiscal 2019.  In particular, Cheon has deep expertise in eCommerce and digital marketing, two areas of critical importance to the success of any brand. As Marketing Director, Interactive, she developed the content and traffic generation strategy for aritzia.com. Later, as Director, eCommerce Marketing and Online Experience, she was part of the team that built Aritzia’s first eCommerce website and was responsible for creating its award-winning online experience. As part of the IPO team, she also created Aritzia’s first-ever investors website.  “As regulations around cannabis-based products come into alignment, there is a tremendous opportunity for brands who can meet both the needs of an increasingly savvy consumer who seeks high-quality, natural products, as well as demonstrate a commitment to acting responsibly,” says Cheon. “Yield’s portfolio is poised to take advantage of this, and I am tremendously excited to be part of shaping these brands.”

Other cannabis-related developments from around the markets include:

Aphria Inc. (NYSE:APHA)(TSX:APHA) reported its results for the first quarter ended August 31, 2019. All amounts are expressed in thousands of Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts.  “We are pleased to report a second consecutive quarter of profitable growth with strong contribution from our Canadian cannabis operations. Our success was also driven by our international business and the strength and growth of our brands, particularly Broken Coast, despite a small fire at our British Columbia facility at the end of the quarter. This solid start to the year keeps us on track to achieve our fiscal year 2020 financial outlook,” stated Irwin D. Simon. “Going forward, we remain focused on our highest-return priorities both in Canada and internationally as our team furthers the development of our medical and adult-use cannabis brands to drive growth through innovation and return value to shareholders.” Net revenue of $126.1 million in the first quarter, an increase of 849% from prior year quarter and decrease of 2% from prior quarter.  Revenue for adult-use cannabis of $20.0 million in the first quarter, an increase of 8% from prior quarter.  Net income of $16.4 million and adjusted EBITDA of $1.0 million in the first quarter. Adjusted EBITDA from cannabis operations of $1.3 million in the first quarter.

Charlotte’s Web Holdings Inc. (CSE:CWEB)(OTCQX:CWBHF) and Nielsen just announced an analytic relationship between the world’s leading CBD brand with the world’s leading market intelligence company. Together, Nielsen and Charlotte’s Web will help guide the U.S. retail market for consumer-packaged goods (CPG) companies through the evolution of the CBD space. Mirroring the changing tide happening across the U.S. retail and CPG industry, this new relationship marks an open and symbiotic relationship that is forming between the emerging CBD industry and the U.S. retail and manufacturing community. Charlotte’s Web is an industry pioneer and the market leader of hemp-CBD extract products. Leveraging its deep product knowledge and category vision, this new relationship will provide unprecedented visibility into market-leading trends, highlighting segments, brands and products that are resonating with consumers in the CBD market. This alliance will also provide insight into consumer attitudes, product preferences, use occasions and future intent tied to consumer interaction points within CPG categories which will help establish Charlotte’s Web as thought leaders and category captains of the hemp CBD category.  Collectively, this powerful suite of information will enable U.S. CPG manufacturers and retailers to more easily measure and predict the impact of hemp CBD on the CPG industry and strategize accordingly. The announcement with Charlotte’s Web comes as Nielsen steadily develops a full suite of cannabis measurement capabilities, inclusive of strategic alliances such as the one with Headset, the leading data and analytics service provider measuring and analyzing the legal Cannabis dispensary channel.

Aurora Cannabis Inc. (NYSE:ACB)(TSX:ACB) and CTT Pharmaceutical Holdings, Inc., announced today the successful commercialization of CTT’s cannabinoid-infused sublingual wafers. The new cannabis product line, a first of its kind, has been launched by Aurora in the Canadian medical cannabis market under the brand name “Dissolve Strips.  Aurora has an ownership interest in CTT of approximately 9%, with a warrant allowing it to increase its stake to 42.5%, and access to CTT’s sublingual wafers drug delivery technology, which is patent protected or patent pending in multiple jurisdictions.  “Aurora’s Dissolve Strips™ provide unique advantages over other ingestible products due to their ease of administration, discrete nature and accurate dosage, that provides more rapid bioavailability of cannabinoids via sublingual use,” said Terry Booth, CEO of Aurora. “This adds yet another innovative offering to our growing portfolio of high quality, medical products that we offer our patient base, and is testament to our industry leading ability to work with technology partners and regulators to bring new form factors to market rapidly.”

Green Growth Brands Inc. (CSE:GGB)(OTCQB:GGBXF) just announced that it has opened its 150^th Seventh Sense Botanical Therapy CBD mall-based shop. The first Seventh Sense shop opened in early February. GGB will provide a sales update on the performance of Seventh Sense® shops and eCommerce on its earnings call for fourth quarter and fiscal year 2019 ended June 30. The call will occur on Thursday, October 24th, 2019.  In the interim, the Company would like to share a progress update on the expansion of Seventh Sense.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated three thousand five hundred dollars for news coverage of upcoming and current press releases issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

$CNPOF $RIV.V to Release Q2 Financial Results, Host Conference Call on November 14

$LXRP 3 Things That Could Characterize the Marijuana 2.0 Launch in Canada

October 22, 2019

October 17 marked the one-year commemoration of recreational marijuana legalization in Canada. After the legalization of marijuana in 2018, Canadian regulators were fast in developing regulations for marijuana leaf and oil products. However, it took them longer to establish rules for cannabis products such as edibles, cannabis-infused drinks, and concentrates used in vape pens. Implementation of the new regulations led to the opening of a new market, referred to as Cannabis 2.0. Below are the three things that could characterize the Cannabis 2.0 market on the day of their legalization.

1. No New Product in the Market

Despite the hype surrounding the launch of the cannabis 2.0 market, the event will not be exciting as it was during the launch of the first marijuana market in Canada because no new cannabis derivative product will be introduced in the market.

Licensed marijuana producers are required by law to issue a 60-day notice to Health Canada before selling marijuana products even though the new regulations for cannabis derivatives are already in effect. The consumers will therefore not be able to get their hands on cannabis derivatives until mid-December.

Since the launch of the cannabis 2.0 market comes before the holiday, it will be a while before it can be determined how the market performs and how the holidays affected sales. Reports for the cannabis 2.0 sales for the first quarter of sales will come in February 2020.

2. Uncertainty Surrounding Cannabis-Infused Beverages And Vaping Products

Analysts and investors will be anxiously waiting for the sales data from the first quarter, which will be more focused on the sale of cannabis-infused beverages and vaping products.

There is much uncertainty surrounding cannabis-infused beverages, and this has forced some companies such as Aurora Cannabis to opt-out of developing cannabis-infused drinks due to the expected low market share of the products, said Cam Battley, the CEO of Aurora Cannabis in the company’s fiscal 2019 Q3 conference in May.

Canopy Growth, in collaboration with Constellation Brands, has developed several types of beverages meant to go up on the shelves later in the year.

Both Aurora and Canopy plan on launching vaping products in the markets, but with the recent scare of vaping-related illness, they are uncertain of how the product will perform and if it will be banned.

3. Cannabis Edibles Will Attract Huge Sales

Due to the skepticism surrounding vaping products and cannabis-infused beverages, cannabis edibles seem like the safest option to introduce during the launch of cannabis 2.0. Thus, most cannabis producers are planning on producing a variety of cannabis edibles.

For example, Aurora Cannabis plans on producing cannabis chocolate, gummies, and mints. According to Bruce Linton, Canopy Growth plans on creating every type of cannabis edible you can come up with. However, when the former CEO of Canopy, Bruce Linton, made these remarks, the new cannabis regulation had not been finalized by Health Canada.

It is thought that marijuana industry players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and IONIC Brands Inc. (CSE: IONC) (OTC: IONKF) would wish to for large market like the U.S. to have a uniform law regulating cannabis in all its forms as is the case in Canada, but that still seems to be far off.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$INMB XPro1595 Highlighted During Press Conference at the Society for Neuroscience

$CNPOF $RIV.V to Report Q2 FY20 Results and Host Earnings Call

TORONTO, Oct. 21, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, will report its second quarter fiscal year 2020 financial results before markets open on Thursday, November 14, 2019. The Company’s unaudited condensed interim consolidated financial statements and management’s discussion and analysis of financial results for the six months ended September 30, 2019 will be available on the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR“) at www.sedar.com and on the Company’s website at www.canopyrivers.com/investors/financials-and-public-filings.

Certain preliminary financial information pertaining to the Company may also be found in the financial results released by Canopy Growth Corporation (TSX: WEED, NYSE: CGC), which are currently scheduled to be released on November 14, 2019. All financial information with respect to the quarter pertaining to the Company in the financial results of Canopy Growth Corporation are preliminary and are unaudited and subject to change and adjustment as the Company prepares its consolidated financial statements for the six months ended September 30, 2019. Accordingly, investors are cautioned not to place undue reliance on the preliminary financial information. The preliminary financial results constitute “forward-looking information” within the meaning of applicable Canadian securities laws and are subject to a number of risks and uncertainties. Actual results may differ materially. See “Forward-looking Statements”.

Following the release of its second quarter fiscal year 2020 financial results, Canopy Rivers will host a conference call and audio webcast with Narbe Alexandrian, President and CEO and Eddie Lucarelli, CFO at 10:00 AM Eastern Time on November 14, 2019.

Webcast Information
A live audio webcast will be available at:
https://event.on24.com/wcc/r/2114597/A2BD47FA291CA7E2389E0AF0D5A10450

Calling Information
North America Toll Free Dial-In Number:
Conference ID: (+1) 888 390 0546

Replay Information
A replay of the call will be accessible by telephone until 11:59 PM Eastern Time on February 14, 2019.
Toll Free Dial-in Number: (+1) 888 390 0541
Replay Password: 448969 #

About Canopy Rivers Inc.

Canopy Rivers is a venture capital firm specializing in cannabis. Its unique investment and operating platform is structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. To the extent any forward-looking information referred to in this news release constitutes “financial outlooks” within the meaning of applicable Canadian securities laws, such information is preliminary financial results for the six months ended September 30, 2019 and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding the timing and availability of the financial results of the Company and Canopy Growth Corporation and the Company’s earnings call.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Financial outlooks, as with forward-looking information generally, are, without limitation, based on assumptions and subject to various risks as set out herein. The Company’s actual financial position and results of operations may differ materially from current expectations. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the preliminary financial results are subject to the completion of the Company’s financial closing procedures and have not been audited or reviewed by the Company’s independent registered public accounting firm; changes in the timing and availability of financial results and the Company’s earnings call; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial markets; potential conflicts of interest; the Canadian regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

$GWPD GrowPods Reduce Costs of Food Production and Stimulate Local Economies

New trend is “Growing Local” to provide fresher produce, reduce energy costs, and help eliminate contamination

CORONA, Calif., Oct. 21, 2019  — GP Solutions (OTC:GWPD), developer of “GrowPods” – proprietary, automated micro-farms, can significantly reduce transportation and energy costs associated with food production, and provide fresher, healthier food than traditional farming and distribution methods.

According to Brian Halweil, author of Eat Here: Reclaiming Homegrown Pleasures in a Global Supermarket, food travels an average of 1,500 miles to get to your plate. Additionally, the longer foods are out of the soil, the less nutritious they become, losing on average 45 percent of their nutrition before being consumed.

Researchers at Iowa State University also looked at a typical meal and found it gobbled up 17-times as much energy in transportation as that same meal raised locally. Dr. Jennifer Wilkins, researcher at Cornell University, added that 20 percent of all fossil fuel use is just for getting food on our table.

The growing trend is to grow food locally. Placing a GrowPod near where food is consumed not only reduces transportation costs, but also uses 90 percent less water than traditional agriculture.

GrowPods provide year-round cultivation, and incorporate automated climate controls and optimized LED lighting to grow more plants per square foot – with yields up to 8 times greater than outdoor farms – while using just a fraction of the water. GrowPods also provide:

• Portability – GrowPods can be set up virtually anywhere
• Scalability – Expanding is as easy as adding additional pods
• Security – Controlled access and entry notification
• Pesticide and Bacteria Free – Sealed environment protects from contaminants and pests

The GrowPod Plug & Grow system is designed for easy operation – allowing users with all levels of experience to rapidly start growing nutritious, robust, and profitable crops. Perfect for entrepreneurs, farmers, schools, grocers, restaurants, and non-profits.

For information, visit: www.growpodsolutions.com, or call (855) 247-8054.

Forward-Looking Statements
This release includes predictions or information that might be considered “forward-looking” within securities laws. These statements represent Company’s current judgments but are subject to uncertainties that could cause actual results to differ. Readers are cautioned to not place undue reliance on these statements, which reflect management’s opinions only as of the date of this release. Company is not obligated to revise statements in light of new information.

Connect:

Email: info@growpodsolutions.com

Website: www.growpodsolutions.com

Facebook: facebook.com/GrowPodTechnology

Twitter: @GrowPodSolution

$INMB Announces Potentially Strong Link Between Obesity and Alzheimer’s

LA JOLLA, Calif., Oct. 21, 2019  — INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today that Dr. Malú Tansey presented data that show the use of INmune Bio’s lead compound, XPro1595, appear to mitigate the exacerbation of Alzheimer’s-like pathology triggered by a high fat and high fructose diet in mice. Dr. Tansey was the lead speaker at a press conference during the Society for Neuroscience (SfN) 49th Annual Meeting, today in Chicago.

 “The new data strengthen our findings that a potential connection between diets rich in fat and sugar and chronic inflammation can lead to an increased risk for Alzheimer’s disease,” said Malú Tansey, Ph.D., Professor of Neuroscience and Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine. “With more than 93 million obese people in the U.S., according to the most recent data from the Centers for Disease Control and Prevention, understanding the link between obesity and Alzheimer’s disease is more relevant now than ever. By targeting inflammation with XPro1595 we may be able to effectively treat neurodegenerative diseases.”

XPro1595 is a novel anti-inflammatory drug that blocks inflammation by selectively neutralizing soluble tumor necrosis factor and it is currently being studied in Australia in a Phase I clinical trial for patients with mild to moderate Alzheimer’s disease who have biomarkers of neuroinflammation.

Dr. Tansey is a leader in the field of neuroinflammation and immune system responses in modulating the gene-environment interactions that determine risk for development and progression of neurodegenerative and neuropsychiatric diseases.

“Finding new ways to stop, treat and prevent Alzheimer’s has been the holy grail of researchers for decades,” said R.J. Tesi, M.D., Chief Executive Officer of INmune Bio. “With more than 200 failed trials, the Company believes that its  novel approach to target neuroinflammation has the potential to change the treatment of neurodegenerative diseases.”

Alzheimer’s disease is the most common cause of dementia and is characterized by chronic inflammation and the decline in cognitive function and neuronal loss. According to the Alzheimer’s Association, more than 5.8 million Americans currently suffer from Alzheimer’s disease and by 2050 the numbers are projected to increase up to 14 million individuals. Alzheimer’s disease is the 6th leading cause of death in the United States with no cure or way to stop or slow the progression of the disease. Currently, there are approximately 47 million people living with Alzheimer’s disease worldwide.

For additional clinical trial details, please refer to https://clinicaltrials.gov/ct2/show/NCT03943264?term=Xpro1595&rank=1

About the Society for Neuroscience (SfN)

The Society for Neuroscience is the world’s largest organization of scientists and physicians devoted to understanding the brain and the nervous system. SfN’s mission is to advance the understanding of the brain and the nervous system by bringing together scientists of diverse backgrounds, by facilitating the integration of research and by encouraging translational research and the application of new scientific knowledge to develop improved disease treatments and cures. SfN is also committed to provide professional development activities, information, and educational resources for neuroscientists at all stages of their careers, to promote public information and general education about the latest neuroscience research and inform legislators and other policymakers.

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause a relapse. INB0c3 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03 and XPro1595 are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com

Media Contact:
David Schull
Russo Partners
(212) 845-4271
David.Schull@russopartnersllc.com

$TGODF Former FDA Boss Calls for Federal Regulation of Marijuana Markets

October 17, 2019

On Monday, Scott Gottlieb, the former Food and Drug Administration Commissioner, said that the federal government should be given the authority to regulate states’ marijuana programs.

In a CNBC appearance, Scott Gottlieb said that the increase in vaping related lung illnesses calls for the need of a federal regulatory system that would give the agencies power to enforce industry standards on all facets of the legal cannabis market such as the potency of THC and the proper methods of consumption.

Although the official was previously not clear on the extent of federal government involvement citing that the vaping problems are due to conflicts between the state and federal laws– he did not say which would be his preferred policy fix. However, last week in a Wall Street Journal editorial, he provided some clarification by saying that federal drug scheduling laws for marijuana should be reformed to offer limited regulations and promote more research on cannabis.

During a TV interview, Gottlieb said that enforcing marijuana prohibition is not politically practicable anymore and that Congress should approve a federal law that allows the enactment of appropriate supervision by the regulatory authorities.

Although he is not in support of the legalization of recreational marijuana and if possible he would like it to shut down completely, the reality of the situation is that many states have already legalized it; thus, any federal system formed would have to accommodate recreational cannabis.

When he was asked if all the states would be in a position to implement all the regulations he has proposed, Gottlieb said no, because some states do not have the capacity nor the resources to control what is being sold in their legal dispensaries as well as shutting down the black market.

He said that for this to be possible, federal authorities are a necessity.

The regulatory model Gottlieb is envisioning is one where the FDA and agencies such as the Drug Enforcement Administration could control the potency of the products, the manufacturing process, the ingredients, and the purpose for which the products are made.

Gottlieb further added that by federalizing marijuana and allowing recreational consumption, they would be in a position where they can limit the types of cannabis products being sold, their potency, and the forms in which it can be consumed. However, he still thinks vaping products should be banned.

He said that the federal agencies should enact strict measures on medical cannabis while holding them to a higher standard and allowing recreational use of the product with lower concentrations of THC, which poses less harm that vaping e-liquids.

He concludes by saying that compromising is right where you allow some form of recreational consumption of marijuana, which is in low concentration in the states allowing it instead of leaving it as it is today where there are no federal laws governing marijuana in those state-legal markets.

Industry analysts believe that companies like VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) and The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) could be seeing lots of sense in the proposals of the former FDA chief.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$INMB Presentation of Data on XPro1595 at SfN Annual Meeting

Data on Neuroinflammation and Alzheimer’s Disease to be Presented by Dr. Malú Tansey; Presentation Selected for Meeting’s Press Conference

LA JOLLA, Calif., Oct. 17, 2019 — INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments that harness the patient’s innate immune system to fight disease, announced today a poster presentation related to the company’s program in Alzheimer’s disease at the upcoming Society for Neuroscience (SfN) 49th Annual Meeting, to be held Oct. 19–23 at McCormick Place in Chicago. In addition, INmune Bio announced that this presentation has been selected for presentation during the meeting’s press conference.

Presented in a poster by Malú Tansey, Ph.D., Professor of Neuroscience and Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine, the data from studies involving the use of INmune Bio’s XPro1595 demonstrate the critical role of the immune system on an individual’s genetic risk in the context of environmental exposures, such as a diet high in fat and sugar, for neurodegenerative diseases such as Alzheimer’s.   The Company believes that  XPro1595 is a next generation anti-inflammatory that crosses the blood-brain barrier to affect neurodegenerative diseases by selectively inhibiting soluble tumor necrosis factor.

“It’s become clear that neurological disorders can arise from or be exacerbated by innate immune dysfunction and chronic inflammation resulting from both genetic and environmental factors such as diet,” said Dr. Tansey. “Harnessing the power of the immune system could potentially delay or perhaps even prevent some of these neurological disorders. Our results provide a compelling rationale for moving forward with a clinical trial in early Alzheimer’s disease patients.”

The SfN Annual Meeting is the premier venue for neuroscientists to present emerging science, learn from experts, forge collaborations with peers and explore new tools and technologies related to the brain and the nervous system.

Poster Details

Session: Alzheimer’s Disease and Other Dementias: Therapeutic Strategies III

Poster number: 564

Presentation Title: Soluble tnf mediates obesogenic diet‑induced alterations in peripheral and brain immunophenotype in a model of Alzheimer’s disease

Time and Date: 1:00 PM, Oct. 22

Location: McCormick Place, Chicago, Illinois

The presentation abstract can be accessed on the SfN website. The above listed date may be subject to change. Details on presentation times or changes to presentation dates can be found on the SfN website. Please check https://www.sfn.org/ for the latest information.

About the Society for Neuroscience (SfN)

The Society for Neuroscience is the world’s largest organization of scientists and physicians devoted to understanding the brain and the nervous system. SfN’s mission is to advance the understanding of the brain and the nervous system by bringing together scientists of diverse backgrounds, by facilitating the integration of research and by encouraging translational research and the application of new scientific knowledge to develop improved disease treatments and cures. SfN is also committed to provide professional development activities, information, and educational resources for neuroscientists at all stages of their careers, to promote public information and general education about the latest neuroscience research and inform legislators and other policymakers.

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause a relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INBO3 and XPro1595 are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com

Media Contact:
David Schull
Russo Partners
(212) 845-4271
David.Schull@russopartnersllc.com

$CNPOF $RIV.V West Virginia Hemp Farmers Unhappy With THC Testing Protocol

$OGI Group Campaigns for Congressional Action on Pesticide-Free Marijuana

$BHAT to Launch New Product AR Dinosaur at China Toy Expo

XIAMEN, China, Oct. 16, 2019 — Blue Hat Interactive Entertainment Technology (“Blue Hat” or the “Company”) (NASDAQ: BHAT), a producer, developer and operator of augmented reality (“AR”) interactive entertainment games and toys in China, today announced that it will launch its new AR Dinosaur toy at the 18th China International Toy Fair (China Toy Expo) which takes place between October 16-18, 2019 in Shanghai, China. Along with the AR Dinosaur, a range of Blue Hat’s popular products will also be on display at the Fair, including the AR Racer, AR Need a Spanking, Bouncing Bubble, and AR Construction Truck products.

New Product Release – AR Dinosaur

AR Dinosaur is an educational toy designed for children aged 5 years and over. Through interactions with the AR Dinosaur physical toy and its mobile application, children can learn a range of information about dinosaurs. The AR Dinosaur is available in five different types of dinosaur, and is enhanced with augmented reality technology.

The AR Dinosaur comes with five physical AR cards that can be placed under the toy to activate its AR features, allowing children to gain knowledge about dinosaurs in an interactive and engaging way. Blue Hat’s advanced research and development allows each type of AR Dinosaur to have their own personality and emotions, which they express by turning their head when they hear a user’s voice, and by making sounds to express how they are feeling. A mobile application designed for the product offers an encyclopedia of information about different types of dinosaur to further enhance the educational value of the product, which will be available for download in the coming months.

Classic Popular Products at the Expo

AR Racer is a car-racing mobile game played using a small physical toy car placed onto the user’s mobile device screen. Users can virtually race one another via a simulated racing track and can also engage in individual races. The physical toy car uses non-adhesive materials to stick to a designated area of the mobile device. Blue Hat’s photosensitive recognition technology allows the toy car to be used as a controller such that when a player encounters an obstacle in the mobile game, the toy car will respond with entertaining actions, such as flashing lights and vibrations that enhance the user experience. 

AR Need a Spanking is an exciting combat game which is played using a ladybug-shaped electronic toy. Blue Hat’s infrared induction technology allows the user’s mobile device to serve as a control panel by which the user controls the movement of the toy for game play in battle dynamics, while simultaneously moving the toy in reality. The user’s mobile device shows a display of virtual enemies while also capturing the position of the toy in the real world, allowing the user to approach or escape its combatants. The program embedded in the toy is used to establish a variety of fun, unique game play mechanics.

Bouncing Bubble is a product designed using specific environmentally-friendly and toxic-free liquid allowing for larger, stronger bubbles that won’t easily pop. Children can bounce these bubbles using a paddle or gloves like ping pong balls, for an extra level of fun than can be provided by conventional bubble products.

The AR Construction Truck product comprises a traditional toy construction truck model which is enhanced with additional interactive features. The product’s accompanying mobile application gives children an audiovisual introduction to the respective features of different construction vehicles, and allows simulated AR operation of the vehicle’s movement, lights and doors.

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games, and toys with mobile game features. The Company’s interactive entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the Company’s investor relations website at http://ir.bluehatgroup.com.

About CTE

The China Toy Expo (CTE), organized by China Toy and Juvenile Product Association, is the largest trade fair for toys and educational products in Asia.

Forward-Looking Statements 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the Company’s SEC filings. These risks and uncertainties could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements.

Contacts:

Melody Liu
Phone: +1 (425) 363-8048
Email: ir@bluehatgroup.net

Sophie Huang
Phone: +86 (592) 550-0129
Email: ir@bluehatgroup.net

$YGYI University of Pennsylvania to Study CBD Use in Dogs

$TGODF Applies Organic Craft Growing Principles to Produce Premium Cannabis

$SRAX CEO to be Interviewed by The Wall Street Resource

$OGI Cannabis 2.0: Canada Set to Legalize CBD Topicals and Beverages

October 15, 2019

Palm Beach, FL – October 15, 2019 — Over the next three days, Canada will legalize CBD all over again.  Just a year after legalizing dried cannabis flower, oils, and sprays, Canada will now legalize edibles, beverages, and topicals this Thursday, October 17, potentially creating sizable opportunity for growth.  Interesting to note, according to analysts at Deloitte, up to 60% of Canadians would use cannabis edible products.  That’s opening a wide range of opportunity for companies including The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF), Aphria Inc. (NYSE:APHA) (TSX:APHA), Charlotte’s Web Holdings Inc. (CSE:CWEB) (OTCQX:CWBHF), OrganiGram Holdings Inc. (TSX-V:OGI) (NASDAQ:OGI), and GW Pharmaceuticals PLC (NASDAQ:GWPH).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced the appointment of Amber Allen as Head of Sales for Yield Growth’s North American retail distribution. Ms. Allen is a seasoned and savvy sales broker bringing decades of experience working with distributors to grow a multitude of brands in the skincare, edible mushrooms and other wellness spaces, including Lavido Skin Care, Love Chock, My Matcha Life, Four Sigmatic, Sun Warrior, Mikei Red Reishi, Thursday Plantation and Kosmea Skin Care.  As part of the Yield Growth team, Amber will be tasked with refining the company’s sales strategy to maximize sales in Canada and the USA with new and existing accounts, leveraging her expansive and long-standing relationships with skincare and wellness retail distributors cultivated over 15 years in the profession. “Amber’s qualifications in selling wellness products for both skin care lines and edible mushroom brands make her an ideal candidate to build out our North American retail presence,” says Penny White, CEO of Yield Growth. “Amber’s experience in building out the sales platform for North American brands is particularly interesting as we prepare to launch out wild edible mushroom brand through our subsidiary Flourish Mushroom Labs.” Amber Allen is the founder of Amber Naturally, a boutique creative firm specializing in sales consulting, social media, content marketing, design, and marketing for natural health and wellness brands. She began her career over fifteen years ago as a personal trainer and nutritionist in Vancouver British Columbia, before parlaying her passion for natural healing into her studies of herbalism and wellness.

Other cannabis-related developments from around the markets include:

Aphria Inc. (NYSE:APHA) (TSX:APHA) will release results for the first quarter and three months ended August 31, 2019 on October 15, 2019 before market open.  Aphria executives will host a conference call to discuss these results at 9:00 am ET. To listen to the live call, dial (888) 231-8191 from Canada and the U.S. or (647) 427-7450 from International locations and use the passcode 6099303. A telephone replay will be available approximately two hours after the call concludes through October 29, 2019.

Charlotte’s Web Holdings Inc. (CSE:CWEB)(OTCQX:CWBHF) and Nielsen just announced an analytic relationship between the world’s leading CBD brand with the world’s leading market intelligence company. Together, Nielsen and Charlotte’s Web will help guide the U.S. retail market for consumer-packaged goods (CPG) companies through the evolution of the CBD space. Mirroring the changing tide happening across the U.S. retail and CPG industry, this new relationship marks an open and symbiotic relationship that is forming between the emerging CBD industry and the U.S. retail and manufacturing community. Charlotte’s Web is an industry pioneer and the market leader of hemp-CBD extract products. Leveraging its deep product knowledge and category vision, this new relationship will provide unprecedented visibility into market-leading trends, highlighting segments, brands and products that are resonating with consumers in the CBD market. This alliance will also provide insight into consumer attitudes, product preferences, use occasions and future intent tied to consumer interaction points within CPG categories which will help establish Charlotte’s Web as thought leaders and category captains of the hemp CBD category.  Collectively, this powerful suite of information will enable U.S. CPG manufacturers and retailers to more easily measure and predict the impact of hemp CBD on the CPG industry and strategize accordingly. The announcement with Charlotte’s Web comes as Nielsen steadily develops a full suite of cannabis measurement capabilities, inclusive of strategic alliances such as the one with Headset, the leading data and analytics service provider measuring and analyzing the legal Cannabis dispensary channel.

OrganiGram Holdings Inc. (TSXV:OGI)(NASDAQ:OGI) just announced the Company was recognized at the Excellence in Manufacturing Consortium Awards of Excellence ceremony in Toronto on October 9.  Organigram was honored with an Outstanding Member Contribution Award for delivering exemplary support to the EMC over the course of the Company’s membership. The award, accepted by Organigram Senior Vice President of Operational Services, Jeff Purcell, recognizes organizations which demonstrate outstanding achievement in manufacturing. “Producing high-quality cannabis in a state-of-the-art indoor environment, Organigram operates in an interesting cross-section of horticulture, consumer packaged goods and manufacturing,” Purcell said. “We are very proud to accept this award and support EMC, a group that sets the standard for manufacturing excellence in Canada.” Organigram was additionally nominated as a finalist in the awards’ Outstanding Manufacturer category.

GW Pharmaceuticals PLC (NASDAQ:GWPH) will announce on November 5th, 2019 its financial results for the third quarter ending September 30^th, 2019. GW will also host a conference call the same day at 4:30 p.m. ET. Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company’s website shortly after the call.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated three thousand six hundred dollars for news coverage of current press releases issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

$CNPOF $RIV.V Receives Milestone Health Canada Licence Amendment

TORONTO, Oct. 15, 2019 – Canopy Rivers (“Canopy Rivers“) (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, today announced that its portfolio company James E. Wagner Cultivation Corporation (“JWC“) (TSXV: JWCA, OTCQX: JWCAF) received a Health Canada licence amendment allowing for cannabis production in four new flowering rooms at its flagship facility in Kitchener, Ontario.

“We believe that this licence amendment demonstrates Health Canada’s recognition of JWC, the quality of its operations, and its disciplined approach to expansion,” said Olivier Dufourmantelle, Chief Operating Officer, Canopy Rivers. “Through its supply agreement with TerrAscend, JWC has an active role in the Canopy Rivers ecosystem. We’ve seen that companies that work together, thrive together, and we think this Health Canada approval will enable JWC to increase production and further collaborate within the Canopy Rivers ecosystem.”

The additional flowering rooms are part of an ongoing program to expand JWC’s existing production capacity. At full-scale, the facility will measure 345,000 square feet. Like the previously licensed space, the newly licensed areas will be equipped with JWC’s proprietary GrowthSTORM™ Dual Droplet™ System. GrowthSTORM™ is an aeroponic method that sees plant roots suspended in the air and misted at regular intervals using specified nutrient solutions adapted for the system. When combined with the GrowthSTORM™ Management system, this method delivers a precise cultivation technique with the ability to collect and analyze data to continually deliver consistent, high-quality cannabis. More information on GrowthSTORM™ can be found on JWC’s website.

Once fully operational, the new flowering rooms will double the facility’s current licensed production capacity from 22,000 square feet, to approximately 44,500 square feet. The additional spaces are composed of two pods, each consisting of two flowering rooms, with each room containing approximately 5,500 square feet of cultivation space.

About Canopy Rivers

Canopy Rivers is a venture capital firm specializing in cannabis. Its unique investment and operating platform is structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the impact of the licence amendment on JWC’s production capacity; the size of JWC’s full-scale facility and JWC’s intention to equip the newly licenced areas with the GrowthSTORM™ Dual Droplet™ System; management’s belief that this Health Canada approval will enable JWC to increase production and further collaborate within the Canopy Rivers ecosystem; and expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; the actual impact of the licence amendment on JWC’s production capacity and ability to collaborate within the Canopy Rivers ecosystem; changes in JWC’s plans with respect to its facility and the newly licenced areas; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

$POAI Subsidiary Takes Part in Groundbreaking Genomes Project

$SRAX Sidesteps a Bullet by Doing What’s Right Amid $55 Billion Tech Data Sector Slump

October 11, 2019

$OGI CBD Oil Social Event Hosted in Birmingham

October 11, 2019

Ever since cannabidiol (CBD) was legalized in Alabama, CBD shops and social events have been popping up like weeds all over the state. Most of them are geared at destigmatizing CBD and pushing their products. On Monday, HempWorx hosted its social event in Jefferson County, and people were invited to come learn all about CBD (and purchase a product or two).

One of the main problems CBD has faced is its continued association with its psychoactive cousin THC. Despite cannabidiol having no psychotropic effects, the two are often lumped together. Thus, the negative light in which THC is usually cast bleeds over onto CBD. It is this stigma that these social events seek to break.

Topher Black, a sales representative from HempWorx, says that most of the people he meets either know all about CBD or have no clue where to even begin. That’s where he steps in, educating them on CBD, where it comes from, and all its benefits.

He explains that there’s a big difference between CBD and THC. Cannabidiol is extracted from the hemp plant while THC comes from marijuana, and they both affect the body in very different ways. While THC will get you high, CBD affects the body differently. It can reduce chronic pain and inflammation, help manage stress and anxiety, among a host of other benefits. HempWorx offers both products that have trace amounts of THC and those that have zero THC content.

Although the state still has a limited number of licensed CBD merchants, folks have long since started planting hemp since it was legalized. The demand for CBD products is there, but it’s still not high enough to warrant an influx of sellers into the market. A few sellers are making a killing, though; some people are selling CBD infused beer, there are CBD infused menus in some coffee shops, and some spas and massage parlors are offering the product too. While the numbers are still low, people are becoming more and more aware of CBD’s host of medical benefits. As word spreads, chances are more people will be willing to give the product a try.

Holding such social events for CBD is an ingenious idea because CBD is still steeped in negative stereotypes, and it has such restrictive marketing regulations that advertising is virtually impossible. These events are therefore a great way to educate the public on CBD, its benefits. Experts believe that CBD industry actors like Neutra Corp. (OTCQB: NTRR) and Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) applaud the creativity that went into organizing the CBD social event.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

$TGODF The Psilocybin Mushroom Story Could be the Next Big Investment Boom

October 10, 2019

Palm Beach, FL – October 10, 2019 –  As the cannabis market booms, another drug may soon follow in its footsteps — psilocybin mushrooms.  Already, we’re seeing a groundswell of interest.  In fact, activists in California are working on getting its decriminalization added to the 2020 ballot.  The proposed amendment – called the California Psilocybin Decriminalization Initiative—would revise state drug laws to decriminalize the “personal possession, storage, use, cultivation, manufacturing, distribution in personal possession amounts, according to Marijuana Moment.  Better, the U.S. FDA already granted “breakthrough status” to COMPASS Pathways’ psilocybin-assisted therapy in October 2018, which allows the FDA assist in the development of a promising drug to treat serious illnesses.  In addition, researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post. As excitement builds, it’s opening a range of opportunity for companies that have already established launching cannabis products including The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF),  GW Pharmaceuticals (NASDAQ:GWPH), Tilray Inc. (NASDAQ:TLRY), Aphria Inc. (NYSE:APHA) (TSX:APHA), and The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF).

The Yield Growth Corp.(CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS:The Yield Growth Corp. just announced that its wholly owned subsidiary Flourish Mushroom Labs Inc. has completed the acquisition, announced on September 24, 2019, of a catalogue of mushroom formulas as the foundation of a mushroom edibles business.  The formulas and know-how acquired relate to formulations that may be used to create ready to eat packaged food products or packaged food products that may be mixed with mushroom varietals of the consumer’s choice. The formulations include soups, teas, hot cocoa, elixirs  and truffles.  Flourish has engaged the developers to create additional products to add to the base catalogue and commercialize the formulas,  going to market first with mushroom based soups and coffees.  “Learning and memory are the core cognitive functions of the human brain,” says Penny White, Yield CEO.” With a rapid decline of age affecting the population cognitive deficit is leading to many neurological diseases. Flourish recognizes the early prevention needed for declining learning and memory to conduct research into creating edible products combining  the mushroom medicine for a broad potential market.” Included in the acquisition is know-how and research related to edible mushrooms that could be used in the formulations and various health benefits that can accrue to people eating those mushrooms, as determined by researching data published from clinical trials and from knowledge of  Chinese, Tibetan and Ayurvedic medicine.  The varieties of mushrooms to be used in the formulations include Lion’s Mane, Turkey Tail, Reishi, Shitake, Chagas, Cordyceps and other wild varietals.  The research and data on health benefits are included in the acquisition by Flourish.  Flourish purchased the formulations and all know-how and data related to the formulations with the issuance of 120,000 common shares of Yield Growth at a deemed value of $0.25 per share.

Other related developments in Yield Growth’s industry include: 

GW Pharmaceuticals PLC (NASDAQ:GWPH) just announced that the European Commission (EC) has approved the marketing authorization for EPIDYOLEX for use as adjunctive therapy of seizures associated with Lennox‑Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older. The approval paves the way for the launch of the medicine across Europe.  “The approval of EPIDYOLEX marks a significant milestone, offering patients and their families the first in a new class of epilepsy medicines and the first and only EMA-approved CBD medicine to treat two severe and life-threatening forms of childhood-onset epilepsy,” said Justin Gover, GW’s CEO. “This approval is the culmination of many years of dedication and collaboration between GW, physicians and the epilepsy community. We believe patients and physicians deserve access to rigorously tested and evaluated cannabis-based medicines, manufactured to the highest standards and approved by medicines regulators, and we are delighted to be the first to offer this solution to the epilepsy community.”

Tilray Inc. (NASDAQ:TLRY) announced it has entered into a definitive agreement pursuant to which Tilray, through a wholly-owned subsidiary of High Park Holdings Ltd. (will acquire all of the issued and outstanding securities of 420 Investments Ltd., an adult-use cannabis retail operator headquartered in Calgary, Alberta.  FOUR20 provides adult-use cannabis consumers with a premium retail experience focused on high quality product selection, education and community. FOUR20 currently operates six licensed retail locations and has 16 additional high-traffic locations secured in desirable locations in Alberta, including Canmore, Calgary and Edmonton. Tilray and High Park will leverage FOUR20’s retail expertise and brand and market knowledge to expand into other Canadian provincial markets where Licensed Producer retail ownership will be permitted in the future.  “FOUR20 offers a premium retail experience for the mainstream cannabis consumer and builds on our broader retail strategy, which includes several minority investments in other leading cannabis retailers,” says Tilray Chief Corporate Development Officer Andrew Pucher. “With FOUR20, we will elevate the retail experience for consumers by offering the best quality-tested products while preparing for the next wave of legalized product launches taking place by year’s end.”

Aphria Inc. (NYSE:APHA) (TSX:APHA) issued the following statement in regards to Aleafia Health Inc.’s termination of the Company’s wholesale cannabis supply agreement with Emblem Corp.  “We are disappointed that Aleafia has chosen to terminate its Agreement with Aphria Inc. The Company had every intention of fulfilling its obligations under the Agreement. As a large shareholder of Aleafia, Aphria made good faith efforts to ensure continuation of the Agreement understanding it was in the best interest of all parties involved. However, the termination of this legacy Agreement frees up significant supply allowing the Company to service its brands that are in high-demand across the country.”  The Parties are contractually obligated to negotiate for a period of 30-days following the receipt of a formal notice of termination. If the Parties fail to arrive at any agreement or settlement within the 30-days, and if Aleafia initiates a formal claim for damages, the Company intends to vigorously defend itself.

The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF) announced that it is reviewing financing alternatives in order to complete construction at its facilities in Ancaster, Ontario and Phase 1a at Valleyfield, Quebec. As previously disclosed, the Company had been engaged in discussions for ordinary course commercial bank facilities and equipment leasing. However, due to changing market conditions, those sources of financing have been unavailable on acceptable terms within the timeframes required, leading the Company to commence a review of additional alternatives. The Company currently has no debt and $56.7 million in cash available in Canada, including $40.2 million in restricted cash allocated to capital expenditures. Construction at Ancaster is largely complete with all grow rooms licensed by Health Canada and approximately 6 weeks left before substantial completion of the processing facility. The evidence package for this final component is expected to be submitted to Health Canada by the end of November for licensing. The Company will prioritize any financing secured to accelerate commercial production in order to ramp-up revenues. TGOD already has supply agreements in place with Alberta, British Columbia and Ontario, and plans to distribute nationally as production increases in 2020. Portfolio development is underway for Cannabis 2.0 with first phase of product launches scheduled for December 2019, including organic teas and infusers.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM was compensated three thousand five hundred dollars for news coverage of current press releases issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

$PBIO BaroShear K45 System Creates Water-Soluble CBD Oil

$OGI Awarded Excellence in Manufacturing Consortium Award

MONCTON, New Brunswick

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that the Company was recognized at the Excellence in Manufacturing Consortium (“EMC”) Awards of Excellence ceremony in Toronto on October 9.

Organigram was honoured with an Outstanding Member Contribution Award for delivering exemplary support to the EMC over the course of the Company’s membership.

The award, accepted by Organigram Senior Vice President of Operational Services, Jeff Purcell, recognizes organizations which demonstrate outstanding achievement in manufacturing.

“Producing high-quality cannabis in a state-of-the-art indoor environment, Organigram operates in an interesting cross-section of horticulture, consumer packaged goods and manufacturing,” Purcell said. “We are very proud to accept this award and support EMC, a group that sets the standard for manufacturing excellence in Canada.”

Organigram was additionally nominated as a finalist in the awards’ Outstanding Manufacturer category.

EMC is a unique non-profit organization dedicated to helping manufacturers grow and become more competitive in growing global marketplaces. The group is responsible for contributing knowledge, expertise and resources toward the success of over 13,000 members. EMC’s total manufacturing audience includes more than 40,000 employers and 600,000 manufacturing employees in every Canadian province.

Over 2019, a group of 50 supervisors and managers from the Company completed the EMC Manufacturing Essentials Program. Program certification equips manufacturing staff with skills to increase workforce productivity.

In September, Organigram hosted an EMC Strategic Interest Group event at its Moncton production facility, where it educated a group of 50 EMC members on its production practices through a first-hand look at facility operations and systems.

“Continuous learning on advancements in emergent tech, innovative solutions and best practices in manufacturing will ensure Organigram can produce world-class products with increasing efficiency and keep pace as the global cannabis market grows,” said Greg Engel, CEO, Organigram. “We look forward to continuing to learn from the group’s vast experience in manufacturing and contribute to the learning of its members by sharing our own experience.”

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information including risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. We seek safe harbor.

For more information about Organigram please visit www.Organigram.ca.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005246/en/

$LXRP Advances Innovation Research Through Agreement with Altria

• The program focuses on the pursuit of reduced risk oral nicotine products that make use of Lexaria’s patented DehydraTECH drug delivery platform
• DehydraTECH has been studied extensively and both human/animal trials confirm its ability to enhance active ingredient absorption in digestible products
• The current research could contribute to the development of oral nicotine products that would usher in a new era of reduced-risk nicotine use

Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) provided an extensive update on advances in its research and development program with Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE: MO). The collaboration focuses on the pursuit of reduced risk oral nicotine consumer products using the Lexaria-patented DehydraTECH technology.

Most of the work within the first phase of the collaborative project has either been completed or is significantly underway. Only one aspect of the project remains to commence imminently, according to a company press release issued on…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

$GGBXF Key Requirements for Starting a Successful CBD Brand

October 10, 2019

In recent years, cannabidiol has become a lot more mainstream than it used to be and the CBD industry is one of the fastest-growing industries in the world. It’s clear that CBD isn’t going anywhere, and entrepreneurs have been flocking to the industry to have a piece of the pie. Every enterprise requires adequate preparation, and starting a successful CBD brand isn’t different. Liam McGreevy and Elliott Findon of Ethnopharm Limited had these tips to share to entrepreneurs looking to join the industry;

Have a Clear Understanding of the Laws and Regulations

Policies on CBD marketing and sale aren’t quite standardized. Having a deep understanding of the local legislation on CBD and other cannabinoids is crucial for business success. Non-compliance could lead to hefty fines and even convictions. Seek legal counsel on matters like product labeling, marketing and other matters that could have legal or regulatory implications. You don’t want the FDA, FTC or other regulators breathing down your neck, do you?

Set Up the Business

Every business needs a cohesive internal structure to run effectively. Relevant legal documents will play a significant role in protecting the business’ and the owner’s interests. Making sure all the relevant documents are in place will ensure operations run smoothly.

Get a Bank Account

You’ll need a place to put all the stacks of money you’ll be making, so it’s wise to get a bank account. Unfortunately, the banking industry is still wary about interacting with CBD merchants. The line between what’s legal or not is pretty thin, and most banks are afraid of being linked with money laundering services. Rome wasn’t built in a day, though, and it’ll take a while before the banking industry is entirely on board. Some banks are supportive, though, while some businesses register as non-CBD entities to access banking services. Do your homework and find a bank that will do business with you.

Brand, Brand and Brand

Building a brand image goes a long way in attracting and retaining customers. Carry out extensive market research and identify your target market. Having your target audience in mind will help you craft a brand that the market will identify with and accept. This is especially important in the CBD industry which has been flooded by a lot of startups jostling for a share of the booming market.

Find Suitable Suppliers

Once you’ve taken care of all that, now you have to stock up. You have the option of getting bulk ingredients or finished products, white-label, private label, or bulk CBD. There’s a whole lot of suppliers, and you’ll have to choose the option that suits you and your business most. Remember, be mindful about getting reputable suppliers of quality products because CBD is largely consumed for health reasons, so your business could tank if the consumers develop questions about the quality of what you sell.

Experts believe that CBD industry players like Grapefruit Boulevard Investments Inc. (OTCQB: IGNG) and Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) have managed to get a foothold in the industry by mastering the concepts above, and much more.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

$SRAX BIGtoken Platform Benefits Customers, Marketers Alike

$YGYI Signs Letter Of Intent With BeneYOU, LLC

Youngevity International, Inc. (NASDAQ: YGYI), a leading multi-channel lifestyle company, and BeneYOU LLC, a nutritional and beauty products company today announced that the parties have executed a non-binding Letter of Intent whereby Youngevity International will purchase certain assets of BeneYOU, LLC.

The parties have acknowledged their plans to execute a definitive Asset Purchase Agreement in the coming weeks with an intention to close the transaction by the end of October.

“We’ve built BeneYOU on principles of integrity, hard work and progressive thinking,” said BeneYOU CEO Ryan Anderson. “Like Youngevity, we know making Customers and Associates the most important factors in our decision-making process leads to their satisfaction. We are especially gratified that the consistencies between our companies are as strong as they are, and we’re hopeful that we can bring this transaction to a successful conclusion by the end of this month.”

Dave Briskie, President and CFO of Youngevity, stated, “Given the size of the integration and the amount of communication that will take place between both companies we felt that disclosing where we are in the acquisition process was prudent. Assuming a successful close, we will share additional information regarding the transaction at that time.”

About Youngevity International, Inc.

Youngevity International, Inc. ( NASDAQ : YGYI ), is a multi-channel lifestyle company operating in 3 distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise. The Company features a multi-country selling network and has assembled a virtual Main Street of products and services under one corporate entity, YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, please visit YGYI.com. Be sure to like us on Facebook and follow us on Twitter.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions and includes statements regarding plans to execute a definitive Asset Purchase Agreement in the coming weeks with an intention to close the transaction by the end of October. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, our ability to consummate the acquisition of the assets of BeneYOU, LLC , our ability to successfully integrate the assets of BeneYOU, LLC, our ability to improve our profitability, expand our liquidity, and strengthen our balance sheet, our ability to continue to maintain compliance with the NASDAQ requirements, the acceptance of the omni-direct approach by our customers, our ability to expand our distribution, our ability to add additional products (whether developed internally or through the BeneYOU, LLC acquisition or other acquisitions), our ability to continue our financial performance and the other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2018 and our subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-Kand the other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2018 and our subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law

Contacts:

Youngevity International, Inc.
Dave Briskie
President and Chief Financial Officer
1 800 982 3189 X6500

Investor Relations
YGYI Investor Relations
800.504.8650
investors@ygyi.com

$POAI Inks its Largest Single-Hospital Sale of Revolutionary STREAMWAY(R) System

• POAI recently announced the sale of 10 FDA-approved, CE-marked STREAMWAY Systems
• STREAMWAY Systems are the first truly continuous, direct-to drain fluid-disposal solutions designed specifically for medical applications
• The announcement is another positive indication that POAI subsidiary Skyline Medical offers tremendous qualitative, long-term potential

In a significant announcement that bodes well for the company, Predictive Oncology Inc. (NASDAQ: POAI) announced that its Skyline Medical Division, producer of the STREAMWAY(R) System, has completed the sale of 10 systems to a major New York hospital (http://nnw.fm/B7hxg). The sale exceeds POAI’s largest single-hospital sale to date, and it is anticipated that the systems collectively will handle 6,000 procedures every year.

The revolutionary FDA-approved, CE-marked STREAMWAY System is the first truly continuous, direct-to drain, fluid-disposal system designed specifically for medical applications such as radiology, endoscopy, surgery, urology and…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

$LXRP DehydraTECH Featured in Human CBD Study Results Published in Clinical Journal